Hub : Traits :

Medication: Amlodipine

57 significantly associated models · 24 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 10435170 12156236 2 2 4.4e-09 8.5e-21 7.6e-13 41 CLCN6 RP4-635E18.7
2 1 27013133 28406173 1 1 9.0e-08 1.1e-05 5.4e-01 98 CD164L2
3 1 112312154 113907148 5 2 1.8e-12 9.4e-15 1.1e-07 53 CTTNBP2NL RHOC
4 2 26291565 27689899 1 1 1.3e-07 6.2e-12 8.8e-07 49 SLC35F6
5 3 26720690 28211713 1 1 1.8e-07 5.3e-07 2.3e-03 63 SLC4A7
6 11 1213806 2640824 2 2 4.4e-12 4.1e-12 1.5e-01 96 LSP1 TNNT3
7 11 99859184 101559718 2 1 1.4e-09 4.8e-09 2.2e-01 96 TMEM133
8 12 121146219 122706844 2 1 1.6e-07 8.8e-08 1.0e+00 100 RNF34
9 15 90730363 92135418 1 1 2.3e-10 6.1e-08 6.0e-01 99 FES
10 17 7269373 7784295 1 1 7.0e-08 5.7e-07 3.9e-03 67 SHBG
11 17 25990033 27387415 1 1 2.6e-07 5.9e-06 1.1e-04 27 TMEM199
12 17 55903829 57920532 5 1 7.1e-09 2.9e-08 2.9e-02 84 SKA2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.43 1 0 0.0 0.00 1.0e+00 FES
Bipolar Disorder or Schizophrenia 2.67 2 1 2.2 0.00 1.0e+00 CLCN6 FES
Neuroticism (Nagel 2018) 0.99 1 0 0.0 0.00 1.0e+00 FES
Schizophrenia (2018) 2.54 1 1 2.2 0.00 1.0e+00 FES
Worry (Nagel 2018) 0.79 1 0 0.0 0.00 1.0e+00 SKA2
Irritable Bowel Disease (IBD) 1.93 1 0 0.0 0.00 1.0e+00 LSP1
Ulcerative Colitis (UC) 1.80 1 0 0.0 0.00 1.0e+00 LSP1
Reaction Time 1.93 1 0 0.0 0.00 1.0e+00 SKA2
Breast Cancer 8.42 4 2 4.4 0.73 2.7e-01 FES LSP1 SLC4A7 TNNT3
Fasting Glucose 1.45 1 0 0.0 0.00 1.0e+00 RNF34
LDL Cholesterol 1.51 1 0 0.0 0.00 1.0e+00 TMEM199
Schizophrenia (2014) 2.15 1 1 2.2 0.00 1.0e+00 FES
Type 2 Diabetes (T2D) (2012) 2.98 1 0 0.0 0.00 1.0e+00 SKA2
Ulcerative Colitis 2.52 1 0 0.0 0.00 1.0e+00 LSP1
Blood Eosinophil Count 0.67 2 0 0.0 0.00 1.0e+00 CD164L2 CLCN6
Blood Platelet Count 1.17 5 2 4.4 -0.83 8.3e-02 CTTNBP2NL LSP1 RHOC SLC4A7 TMEM199
Blood Red Count 1.11 6 1 2.2 -0.35 5.0e-01 CLCN6 FES LSP1 RHOC SHBG SLC35F6
Blood White Count 1.20 5 1 2.2 -0.22 7.2e-01 FES LSP1 SLC35F6 SLC4A7 TMEM133
Heel T-Score 1.93 6 4 8.9 -0.57 2.4e-01 CTTNBP2NL RHOC RP4-635E18.7 SLC4A7 TMEM133 TMEM199
BMI 0.99 3 0 0.0 0.00 1.0e+00 CLCN6 RNF34 SLC35F6
Height 1.47 11 4 8.9 -0.65 2.9e-02 FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199 TNNT3
Waist Hip Ratio (WHR) 1.22 2 0 0.0 0.00 1.0e+00 SHBG TNNT3
Systolic Blood Pressure 26.67 15 12 26.7 0.86 3.3e-05 CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TMEM199 TNNT3
Smoking Status 0.85 1 0 0.0 0.00 1.0e+00 FES
Allergy or Eczema 2.25 3 0 0.0 0.00 1.0e+00 CLCN6 FES RNF34
Cardiovascular Disease 19.93 14 13 28.9 0.94 7.4e-07 CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TNNT3
Respiratory disease 1.78 2 0 0.0 0.00 1.0e+00 FES SHBG
Type 2 Diabetes (T2D) (2018) 1.31 1 0 0.0 0.00 1.0e+00 SKA2
Lung FEV1/FVC ratio 1.29 2 2 4.4 0.00 1.0e+00 CTTNBP2NL TMEM133
Lung FVC 0.91 2 0 0.0 0.00 1.0e+00 CLCN6 CTTNBP2NL
Chronotype (morning person) 1.35 1 0 0.0 0.00 1.0e+00 SKA2
Hair Pigment 0.24 2 1 2.2 0.00 1.0e+00 FES TMEM133
Tanning 0.29 2 0 0.0 0.00 1.0e+00 CLCN6 TMEM133
Hand grip strength (left) 1.53 3 0 0.0 0.00 1.0e+00 FES RHOC SHBG
Number of treatments/medications taken 4.34 3 1 2.2 0.00 1.0e+00 FES RHOC TMEM133
Sensitivity / hurt feelings 2.20 2 1 2.2 0.00 1.0e+00 FES SKA2
Systolic blood pressure, automated reading 18.98 10 7 15.6 0.90 4.6e-04 CLCN6 FES LSP1 RHOC RP4-635E18.7 SHBG SLC4A7 TMEM133 TMEM199 TNNT3
Angina 3.93 2 1 2.2 0.00 1.0e+00 FES TMEM133
Impedance of leg (right) 1.99 7 1 2.2 0.13 7.8e-01 CD164L2 FES RHOC SHBG SLC35F6 SLC4A7 TMEM133
Leg fat-free mass (left) 1.70 6 0 0.0 -0.54 2.6e-01 FES RP4-635E18.7 SHBG SLC35F6 TMEM133 TMEM199
Trunk fat percentage 1.57 3 0 0.0 0.00 1.0e+00 RNF34 SHBG TNNT3
Hand grip strength (right) 1.86 2 0 0.0 0.00 1.0e+00 RHOC SHBG
Age when periods started (menarche) 1.79 2 0 0.0 0.00 1.0e+00 LSP1 TNNT3
Heel bone mineral density (BMD) T-score, automated (left) 1.78 2 0 0.0 0.00 1.0e+00 TMEM133 TMEM199
High blood pressure 23.58 14 13 28.9 0.94 4.1e-07 CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TNNT3
Hayfever, allergic rhinitis or eczema 1.91 3 0 0.0 0.00 1.0e+00 CLCN6 FES RNF34
Medication: Atenolol 8.71 5 1 2.2 0.96 9.5e-03 CLCN6 FES RHOC TMEM133 TNNT3
Sitting height 1.28 5 1 2.2 0.44 4.6e-01 CD164L2 FES SHBG SLC35F6 SLC4A7
High blood pressure (mother) 10.92 8 1 2.2 0.91 1.7e-03 CLCN6 FES LSP1 RHOC RNF34 SLC4A7 TMEM133 TNNT3
Body mass index (BMI) 0.81 2 0 0.0 0.00 1.0e+00 RNF34 SKA2
Impedance of leg (left) 2.02 6 1 2.2 0.20 7.1e-01 CD164L2 FES RHOC SHBG SLC35F6 TMEM133
Leg predicted mass (left) 1.69 6 0 0.0 -0.54 2.6e-01 FES RP4-635E18.7 SHBG SLC35F6 TMEM133 TMEM199
Trunk fat mass 1.21 1 0 0.0 0.00 1.0e+00 RNF34
Waist circumference 1.00 1 0 0.0 0.00 1.0e+00 SKA2
Number of incorrect matches in round 1.50 1 0 0.0 0.00 1.0e+00 FES
Alcohol usually taken with meals 1.93 1 0 0.0 0.00 1.0e+00 FES
Had other major operations 2.47 1 0 0.0 0.00 1.0e+00 SHBG
Forced vital capacity (FVC) 1.42 2 1 2.2 0.00 1.0e+00 RHOC TMEM133
Heel bone mineral density (BMD) T-score, automated (right) 1.71 2 0 0.0 0.00 1.0e+00 TMEM133 TMEM199
Heart attack 3.38 2 1 2.2 0.00 1.0e+00 CD164L2 FES
Allergy 2.02 3 0 0.0 0.00 1.0e+00 CLCN6 FES RNF34
Medication: Ramipril 6.78 4 1 2.2 0.99 1.2e-02 FES LSP1 TMEM133 TNNT3
Medication: Simvastatin 4.36 2 1 2.2 0.00 1.0e+00 FES TMEM133
Illnesses of siblings 5.15 5 1 2.2 0.12 8.5e-01 CLCN6 FES RHOC SLC4A7 TMEM133
Weight 1.26 3 0 0.0 0.00 1.0e+00 RP4-635E18.7 SKA2 SLC35F6
Impedance of arm (right) 1.88 4 1 2.2 -0.48 5.2e-01 LSP1 SHBG SLC4A7 TNNT3
Arm fat percentage (right) 1.34 1 0 0.0 0.00 1.0e+00 RNF34
Trunk fat-free mass 2.02 5 2 4.4 -0.27 6.6e-01 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Hip circumference 1.28 2 1 2.2 0.00 1.0e+00 CLCN6 SKA2
Father's age at death 2.48 1 1 2.2 0.00 1.0e+00 FES
Hair/balding pattern: Pattern 3 1.04 1 0 0.0 0.00 1.0e+00 CLCN6
Forced expiratory volume in 1-second (FEV1) 1.28 2 0 0.0 0.00 1.0e+00 RHOC TMEM133
Asthma 1.70 2 0 0.0 0.00 1.0e+00 CLCN6 FES
Medication: Cholesterol lowering 4.73 3 2 4.4 0.00 1.0e+00 CLCN6 FES TMEM133
Illnesses of mother 6.75 2 1 2.2 0.00 1.0e+00 FES TMEM133
Forced expiratory volume in 1-second (FEV1), Best measure 1.00 2 0 0.0 0.00 1.0e+00 RHOC TMEM133
Pulse wave Arterial Stiffness index 2.50 2 0 0.0 0.00 1.0e+00 CLCN6 FES
Impedance of arm (left) 1.99 4 1 2.2 -0.46 5.4e-01 LSP1 SHBG SLC4A7 TNNT3
Arm fat mass (right) 1.01 1 0 0.0 0.00 1.0e+00 RNF34
Trunk predicted mass 2.01 5 2 4.4 -0.27 6.6e-01 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Standing height 1.25 5 2 4.4 -0.66 2.2e-01 LSP1 RHOC RP4-635E18.7 SHBG SLC35F6
Breastfed as a baby 1.59 1 0 0.0 0.00 1.0e+00 FES
Hair/balding pattern: Pattern 4 1.35 1 0 0.0 0.00 1.0e+00 FES
Birth weight of first child 4.91 2 2 4.4 0.00 1.0e+00 CLCN6 FES
Headache pain in last month 2.00 2 0 0.0 0.00 1.0e+00 FES SKA2
Medication for cholesterol, blood pressure or diabetes 11.80 7 3 6.7 -0.05 9.1e-01 CLCN6 CTTNBP2NL FES LSP1 RHOC SLC4A7 TMEM133
Birth weight 3.01 1 1 2.2 0.00 1.0e+00 FES
High blood pressure (siblings) 9.22 6 2 4.4 0.98 8.2e-04 CLCN6 FES RHOC SLC4A7 TMEM133 TNNT3
Forced vital capacity (FVC), Best measure 1.11 1 0 0.0 0.00 1.0e+00 RHOC
Body fat percentage 1.50 3 0 0.0 0.00 1.0e+00 CLCN6 RNF34 SHBG
Leg fat percentage (right) 1.30 3 0 0.0 0.00 1.0e+00 CLCN6 RNF34 SKA2
Arm fat-free mass (right) 1.70 5 1 2.2 -0.25 6.9e-01 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Pulse wave peak to peak time 2.56 2 0 0.0 0.00 1.0e+00 CLCN6 FES
Medication: Blood pressure 17.86 11 7 15.6 0.94 1.9e-05 CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SLC4A7 TMEM133 TNNT3
Angina (self-reported) 3.91 2 1 2.2 0.00 1.0e+00 FES TMEM133
Medication: Allopurinol 1.03 1 0 0.0 0.00 1.0e+00 SHBG
Mean time to correctly identify matches 2.35 3 0 0.0 0.00 1.0e+00 FES SKA2 SLC4A7
Heart disease (mother) 3.39 2 0 0.0 0.00 1.0e+00 FES SLC4A7
Whole body fat mass 1.08 1 0 0.0 0.00 1.0e+00 RNF34
Leg fat mass (right) 0.94 1 0 0.0 0.00 1.0e+00 RNF34
Arm predicted mass (right) 1.77 4 1 2.2 -0.12 8.8e-01 SHBG SLC35F6 SLC4A7 TMEM199
Pulse rate, automated reading 1.47 2 0 0.0 0.00 1.0e+00 SHBG SLC4A7
Comparative height size at age 10 0.82 2 1 2.2 0.00 1.0e+00 FES RP4-635E18.7
Suffer from 'nerves' 1.12 1 0 0.0 0.00 1.0e+00 SKA2
Medication: Aspirin 4.84 2 1 2.2 0.00 1.0e+00 FES RNF34
Hypertension (Self-reported) 23.68 14 13 28.9 0.94 5.5e-07 CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TNNT3
Gastro-oesophageal reflux (gord) / gastric reflux (Self-reported) 1.52 1 0 0.0 0.00 1.0e+00 RNF34
Illnesses of father: Heart disease 3.80 1 1 2.2 0.00 1.0e+00 FES
Whole body fat-free mass 1.89 6 2 4.4 -0.31 5.5e-01 FES SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Leg fat-free mass (right) 1.81 7 1 2.2 -0.32 4.8e-01 FES RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Arm fat percentage (left) 1.42 2 0 0.0 0.00 1.0e+00 RNF34 SHBG
Handedness (chirality/laterality): Left-handed 1.43 1 0 0.0 0.00 1.0e+00 FES
Friendships satisfaction 1.44 1 0 0.0 0.00 1.0e+00 SLC35F6
Medication for cholesterol 10.23 10 3 6.7 -0.99 2.7e-08 CD164L2 CLCN6 FES LSP1 RHOC RNF34 RP4-635E18.7 SLC35F6 TMEM133 TNNT3
Mineral and other dietary supplements 1.25 1 0 0.0 0.00 1.0e+00 FES
Breast cancer (self-reported) 2.74 1 1 2.2 0.00 1.0e+00 SLC4A7
Asthma (self-reported) 1.69 1 0 0.0 0.00 1.0e+00 FES
Medication: Aspirin 5.43 2 1 2.2 0.00 1.0e+00 FES RNF34
Illnesses of father: None of the above (group 1) 4.71 1 1 2.2 0.00 1.0e+00 FES
Forced expiratory volume in 1-second (FEV1), predicted percentage 0.90 1 0 0.0 0.00 1.0e+00 TMEM133
Whole body water mass 1.90 7 2 4.4 -0.34 4.5e-01 FES RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Leg predicted mass (right) 1.83 7 1 2.2 -0.33 4.7e-01 FES RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Arm fat mass (left) 1.02 1 0 0.0 0.00 1.0e+00 RNF34
Number of self-reported non-cancer illnesses 4.52 3 0 0.0 0.00 1.0e+00 CLCN6 RNF34 TMEM133
Mother's age at death 2.88 1 0 0.0 0.00 1.0e+00 CLCN6
Medication: Blood pressure 19.96 13 7 15.6 0.97 7.4e-08 CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TNNT3
High cholesterol (Self-reported) 4.02 4 1 2.2 0.20 8.0e-01 CD164L2 CLCN6 FES TMEM133
Medication: Bendroflumethiazide 15.83 12 7 15.6 0.98 2.0e-08 CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TNNT3
Medication: Lisinopril 5.66 4 0 0.0 -0.88 1.2e-01 FES LSP1 RHOC TMEM133
Illnesses of father: High blood pressure 8.70 5 1 2.2 0.71 1.8e-01 CLCN6 FES LSP1 SLC4A7 TMEM133
Ever smoked 1.37 2 0 0.0 0.00 1.0e+00 FES RNF34
Basal metabolic rate 1.71 5 1 2.2 -0.50 3.9e-01 RP4-635E18.7 SHBG SLC35F6 TMEM133 TMEM199
Leg fat percentage (left) 1.22 2 0 0.0 0.00 1.0e+00 CLCN6 RNF34
Arm fat-free mass (left) 1.78 4 1 2.2 -0.14 8.6e-01 SHBG SLC35F6 SLC4A7 TMEM199
Risk taking 1.46 1 0 0.0 0.00 1.0e+00 FES
Age started oral contraceptive pill 1.36 1 0 0.0 0.00 1.0e+00 FES
Diastolic blood pressure, automated reading 13.28 7 6 13.3 0.87 1.1e-02 CLCN6 FES LSP1 RHOC RP4-635E18.7 TMEM133 TNNT3
Myopia 1.19 1 0 0.0 0.00 1.0e+00 RHOC
Vascular/heart problems diagnosed by doctor 22.35 14 11 24.4 -0.93 1.7e-06 CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TNNT3
Cholesterol lowering medication 3.45 1 0 0.0 0.00 1.0e+00 RNF34
Heart attack/myocardial infarction (self-reported) 3.28 2 1 2.2 0.00 1.0e+00 CD164L2 FES
Heart disease (siblings) 2.01 1 0 0.0 0.00 1.0e+00 FES
Impedance of whole body 1.92 6 1 2.2 -0.21 6.9e-01 LSP1 SHBG SLC35F6 SLC4A7 TMEM133 TNNT3
Leg fat mass (left) 0.88 1 0 0.0 0.00 1.0e+00 RNF34
Arm predicted mass (left) 1.82 4 1 2.2 -0.14 8.6e-01 SHBG SLC35F6 SLC4A7 TMEM199

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 1 0.029 1.5
GTEx Adipose Visceral Omentum 0 0.000 1.5
GTEx Adrenal Gland 1 0.069 1.5
GTEx Artery Aorta 3 0.101 1.5
GTEx Artery Coronary 0 0.000 1.5
GTEx Artery Tibial 4 0.106 1.5
GTEx Brain Caudate basal ganglia 0 0.000 1.4
GTEx Brain Cerebellar Hemisphere 0 0.000 1.3
GTEx Brain Cerebellum 0 0.000 1.4
GTEx Brain Cortex 0 0.000 1.4
GTEx Brain Frontal Cortex BA9 0 0.000 1.4
GTEx Brain Hippocampus 0 0.000 1.5
GTEx Brain Hypothalamus 0 0.000 1.4
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.4
GTEx Brain Putamen basal ganglia 0 0.000 1.3
GTEx Breast Mammary Tissue 0 0.000 1.5
GTEx Breast Mammary Tissue (Male) 1 0.084 1.4
GTEx Breast Mammary Tissue (Female) 0 0.000 1.5
GTEx Cells EBV-transformed lymphocytes 0 0.000 1.4
GTEx Cells Transformed fibroblasts 3 0.071 1.4
GTEx Colon Sigmoid 0 0.000 1.5
GTEx Colon Transverse 0 0.000 1.5
GTEx Esophagus Gastroesophageal Junction 0 0.000 1.5
GTEx Esophagus Mucosa 0 0.000 1.4
GTEx Esophagus Muscularis 0 0.000 1.5
GTEx Heart Atrial Appendage 0 0.000 1.4
GTEx Heart Left Ventricle 0 0.000 1.4
GTEx Liver 0 0.000 1.3
GTEx Lung 2 0.070 1.5
GTEx Muscle Skeletal 2 0.069 1.4
GTEx Nerve Tibial 3 0.069 1.4
GTEx Ovary 0 0.000 1.5
GTEx Pancreas 0 0.000 1.5
GTEx Pituitary 0 0.000 1.4
GTEx Prostate 0 0.000 1.5
GTEx Skin Not Sun Exposed Suprapubic 1 0.041 1.5
GTEx Skin Sun Exposed Lower leg 0 0.000 1.4
GTEx Small Intestine Terminal Ileum 0 0.000 1.4
GTEx Spleen 0 0.000 1.5
GTEx Stomach 1 0.069 1.5
GTEx Testis 1 0.032 1.4
GTEx Thyroid 0 0.000 1.4
GTEx Uterus 0 0.000 1.4
GTEx Vagina 0 0.000 1.5
GTEx Whole Blood 1 0.050 1.4
METSIM Adipose 2 0.043 1.4
NTR Blood 0 0.000 1.4
ROSMAP Brain Pre-frontal Cortex 2 0.046 1.5
YFS Blood 1 0.022 1.3
CommonMind Brain Pre-frontal Cortex 2 0.037 1.4
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.3
The Cancer Genome Atlas Breast Invasive Carcinoma 2 0.045 1.4
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 2 0.182 1.4
The Cancer Genome Atlas Colon Adenocarcinoma 0 0.000 1.4
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.3
The Cancer Genome Atlas Glioblastoma Multiforme 0 0.000 1.4
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 4 0.147 1.4
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 3 0.073 1.4
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 1 0.049 1.4
The Cancer Genome Atlas Brain Lower Grade Glioma 1 0.023 1.4
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 1 0.090 1.4
The Cancer Genome Atlas Lung Adenocarcinoma 2 0.068 1.4
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 2 0.080 1.4
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 1 0.063 1.4
The Cancer Genome Atlas Pancreatic Adenocarcinoma 0 0.000 1.4
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 0 0.000 1.3
The Cancer Genome Atlas Prostate Adenocarcinoma 1 0.022 1.4
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.4
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.4
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 1.3
The Cancer Genome Atlas Stomach Adenocarcinoma 1 0.059 1.4
The Cancer Genome Atlas Testicular Germ Cell Tumors 0 0.000 1.3
The Cancer Genome Atlas Thyroid Carcinoma 3 0.058 1.3
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.6